Literature DB >> 12377802

High prevalence of osteoporotic vertebral fractures in patients with Crohn's disease.

J Klaus1, G Armbrecht, M Steinkamp, J Brückel, A Rieber, G Adler, M Reinshagen, D Felsenberg, C von Tirpitz.   

Abstract

BACKGROUND AND AIMS: Osteopenia and osteoporosis are frequent in Crohn's disease. However, there are few data on related vertebral fractures. Therefore, we evaluated prospectively the prevalence of osteoporotic vertebral fractures in these patients.
METHODS: A total of 293 patients were screened with dual energy x ray absorptiometry of the lumbar spine (L1-L4) and proximal right femur. In 156 patients with lumbar osteopenia or osteoporosis (T score <-1), x ray examinations of the thoracic and lumbar spine were performed. Assessment of fractures included visual reading of x rays and quantitative morphometry of the vertebral bodies (T4-L4), analogous to the criteria of the European Vertebral Osteoporosis Study.
RESULTS: In 34 (21.8%; 18 female) of 156 Crohn's disease patients with reduced bone mineral density, 63 osteoporotic vertebral fractures (50 fx. (osteoporotic fracture with visible fracture line running into the vertebral body and/or change of outer shape) and 13 fxd. (osteoporotic fracture with change of outer shape but without visible fracture line)) were found, 50 fx. in 25 (16%, 15 female) patients and 13 fxd. in nine (5.8%, three female) patients. In four patients the fractures were clinically evident and associated with severe back pain. Approximately one third of patients with fractures were younger than 30 years. Lumbar bone mineral density was significantly reduced in patients with fractures compared with those without (T score -2.50 (0.88) v -2.07 (0.66); p<0.025) but not at the hip (-2.0 (1.1) v -1.81 (0.87); p=0.38). In subgroups analyses, no significant differences were observed.
CONCLUSIONS: In patients with Crohn's disease and reduced bone mineral density, the prevalence of vertebral fractures-that is, manifest osteoporosis-was strikingly high at 22%, even in those aged less than 30 years, a problem deserving further clinical attention.

Entities:  

Mesh:

Year:  2002        PMID: 12377802      PMCID: PMC1773437          DOI: 10.1136/gut.51.5.654

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  47 in total

1.  Bone mineral density in patients with recently diagnosed inflammatory bowel disease.

Authors:  E J Schoon; B M Blok; B J Geerling; M G Russel; R W Stockbrügger; R J Brummer
Journal:  Gastroenterology       Date:  2000-11       Impact factor: 22.682

2.  A four-year longitudinal study of bone loss in patients with inflammatory bowel disease.

Authors:  R J Motley; D Clements; W D Evans; E O Crawley; C Evans; J Rhodes; J E Compston
Journal:  Bone Miner       Date:  1993-11

3.  Low bone mineral density in Crohn's disease, but not in ulcerative colitis, at diagnosis.

Authors:  S Ghosh; S Cowen; W J Hannan; A Ferguson
Journal:  Gastroenterology       Date:  1994-10       Impact factor: 22.682

Review 4.  Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  1994

5.  The diagnosis of osteoporosis.

Authors:  J A Kanis; L J Melton; C Christiansen; C C Johnston; N Khaltaev
Journal:  J Bone Miner Res       Date:  1994-08       Impact factor: 6.741

6.  Genetic factors determine extent of bone loss in inflammatory bowel disease.

Authors:  C M Schulte; A U Dignass; H Goebell; H D Röher; K M Schulte
Journal:  Gastroenterology       Date:  2000-10       Impact factor: 22.682

7.  The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study.

Authors:  C N Bernstein; J F Blanchard; W Leslie; A Wajda; B N Yu
Journal:  Ann Intern Med       Date:  2000-11-21       Impact factor: 25.391

8.  Longitudinal study of cortical bone loss in patients with inflammatory bowel disease.

Authors:  D Clements; R J Motley; W D Evans; A D Harries; J Rhodes; R J Coles; J E Compston
Journal:  Scand J Gastroenterol       Date:  1992-12       Impact factor: 2.423

Review 9.  The epidemiology of vertebral fractures. European Vertebral Osteoporosis Study Group.

Authors:  C Cooper; T O'Neill; A Silman
Journal:  Bone       Date:  1993       Impact factor: 4.398

10.  Hormone replacement therapy prevents bone loss in patients with inflammatory bowel disease.

Authors:  D Clements; J E Compston; W D Evans; J Rhodes
Journal:  Gut       Date:  1993-11       Impact factor: 23.059

View more
  38 in total

Review 1.  Extraintestinal complications of inflammatory bowel disease.

Authors:  Tim Orchard
Journal:  Curr Gastroenterol Rep       Date:  2003-12

2.  Measurement of vitamin D levels in inflammatory bowel disease patients reveals a subset of Crohn's disease patients with elevated 1,25-dihydroxyvitamin D and low bone mineral density.

Authors:  M T Abreu; V Kantorovich; E A Vasiliauskas; U Gruntmanis; R Matuk; K Daigle; S Chen; D Zehnder; Y-C Lin; H Yang; M Hewison; J S Adams
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

3.  Use of exclusive enteral nutrition is just as effective as corticosteroids in newly diagnosed pediatric Crohn's disease.

Authors:  Jason Soo; Bushra A Malik; Justine M Turner; Rabin Persad; Eytan Wine; Kerry Siminoski; Hien Q Huynh
Journal:  Dig Dis Sci       Date:  2013-09-12       Impact factor: 3.199

4.  Ileum resection is the most predictive factor for osteoporosis in patients with Crohn's disease.

Authors:  R A van Hogezand; D Bänffer; A H Zwinderman; E V McCloskey; G Griffioen; N A T Hamdy
Journal:  Osteoporos Int       Date:  2006-01-04       Impact factor: 4.507

5.  Risk of diagnosed fractures in children with inflammatory bowel diseases.

Authors:  Michael D Kappelman; Joseph A Galanko; Carol Q Porter; Robert S Sandler
Journal:  Inflamm Bowel Dis       Date:  2010-09-24       Impact factor: 5.325

6.  Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial.

Authors:  Jason R Westin; Michael A Thompson; Vince D Cataldo; Luis E Fayad; Nathan Fowler; Michelle A Fanale; Saatva Neelapu; Felipe Samaniego; Jorge Romaguera; Jatin Shah; Peter McLaughlin; Barbara Pro; Larry W Kwak; Perpetua Sanjorjo; William A Murphy; Camillo Jimenez; Bela Toth; Wenli Dong; Fredrick B Hagemeister
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2012-12-29

7.  Official positions of the International Society for Clinical Densitometry (ISCD) on DXA evaluation in children and adolescents.

Authors:  Maria Luisa Bianchi; Sanford Baim; Nick J Bishop; Catherine M Gordon; Didier B Hans; Craig B Langman; Mary B Leonard; Heidi J Kalkwarf
Journal:  Pediatr Nephrol       Date:  2009-07-15       Impact factor: 3.714

8.  Risk factors for low bone mineral density in children and adolescents with inflammatory bowel disease.

Authors:  Letícia Helena Caldas Lopes; Vera Lucia Sdepanian; Vera Lúcia Szejnfeld; Mauro Batista de Morais; Ulysses Fagundes-Neto
Journal:  Dig Dis Sci       Date:  2008-03-20       Impact factor: 3.199

9.  Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status.

Authors:  B L Langdahl; F Marin; E Shane; H Dobnig; J R Zanchetta; M Maricic; K Krohn; K See; M R Warner
Journal:  Osteoporos Int       Date:  2009-04-07       Impact factor: 4.507

Review 10.  Chronic pediatric inflammatory diseases: effects on bone.

Authors:  Anuradha Viswanathan; Francisco A Sylvester
Journal:  Rev Endocr Metab Disord       Date:  2007-12-29       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.